Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle

European Journal of Pharmacology

Volumn 635, Issue 1-3, 2010, Pages 212-218

  Munoz, Lenka ^a   Ramsay, Emma E ^a   Manetsch, Melanie ^a   Ge, Qi ^b   Peifer, Christian ^c   Laufer, Stefan ^c   Ammit, Alaina J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Airway remodelling; Airway smooth muscle; Asthma; Inflammation; ML3403; P38 MAPK

Indexed keywords

3 HYDROXY 1 (3 HYDROXYPROPYL) 2 METHYL 4 PYRIDINONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [5 (4 FLUOROPHENYL) 2 METHYLSULFANYL 3H IMIDAZOL 4 YL]PYRIDIN 2 YL (1 PHENYLETHYL)AMINE; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ML 3403; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BREATHING MUSCLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN SECRETION; SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS; ASTHMA; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; INTERLEUKIN-6; INTERLEUKIN-8; ISOENZYMES; MUSCLE, SMOOTH; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RESPIRATORY SYSTEM; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952319119     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.037     Document Type: Article

References (25)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with image. J. Biophotonics Int. 2004, 11:36-42.
2. Amrani Y., Ammit A.J., Panettieri R.A. Tumor necrosis factor receptor (TNFR) 1, but not TNFR2, mediates tumor necrosis factor-alpha-induced interleukin-6 and RANTES in human airway smooth muscle cells: role of p38 and p42/44 mitogen-activated protein hinases. Mol. Pharmacol. 2001, 60:646-655.
3. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
4. Dominguez C., Powers D.A., Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Dev. 2005, 8:421-430.
5. Duan W., Wong W.S. Targeting mitogen-activated protein kinases for asthma. Curr. Drug Targets 2006, 7:691-698.
6. Duan W., Chan J.H., McKay K., Crosby J.R., Choo H.H., Leung B.P., Karras J.G., Wong W.S. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 2005, 171:571-578.
7. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23:329-336.
8. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keef S.J., O'Neill E.A. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998, 37:13846-13853.
9. Hallsworth M.P., Moir L.M., Lai D., Hirst S.J. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am. J. Respir. Crit. Care Med. 2001, 164:688-697.
10. Hedges J.C., Singer C.A., Gerthoffer W.T. Mitogen-activated protein kinases regulate cytokine gene expression in human airway myocytes. Am. J. Respir. Cell Mol. Biol. 2000, 23:86-94.
11. Henness S., Johnson C.K., Ge Q., Armour C.L., Hughes J.M., Ammit A.J. IL-17A augments TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J. Allergy Clin. Immunol. 2004, 114:958-964.
12. Henness S., van Thoor E., Ge Q., Armour C.L., Hughes J.M., Ammit A.J. IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. Am. J. Physiol. 2006, 290:L1283-L1290.
13. Johnson P.R., Armour C.L., Carey D., Black J.L. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am. J. Physiol. 1995, 269:L514-L519.
14. Kammerer B., Scheible H., Albrecht W., Gleiter C.H., Laufer S. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor. Drug Metab. Dispos. 2007, 35:875-883.
15. Laufer S.A., Wagner G.K., Kotschenreuther D.A., Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 2003, 46:3230-3244.
16. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
17. Margutti S., Laufer S.A. Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem 2007, 2:1116-1140.
18. Newton R., Holden N. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma?. BioDrugs 2003, 17:113-129.
19. Orsini M.J., Krymskaya V.P., Eszterhas A.J., Benovic J.L., Panettieri R.A., Penn R.B. MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation. Am. J. Physiol. 1999, 277:L479-L488.
20. Peifer C., Wagner G., Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 2006, 6:113-149.
21. Peifer C., Kinkel K., Abadleh M., Schollmeyer D., Laufer S. From five- to six-membered rings: 3, 4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. J. 2Med. Chem. 2007, 50:1213-1221.
22. Peifer C., Urich R., Schattel V., Abadleh M., Rottig M., Kohlbacher O., Laufer S. Implications for selectivity of 3, 4-diarylquinolinones as p38α MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:1431-1435.
23. Pelaia G., Cuda G., Vatrella A., Gallelli L., Caraglia M., Marra M., Abbruzzese A., Caputi M., Maselli R., Costanzo F.S., Marsico S.A. Mitogen-activated protein kinases and asthma. J. Cell. Physiol. 2005, 202:642-653.
24. Quante T., Ng Y.C., Ramsay E.E., Henness S., Allen J.C., Parmentier J., Ge Q., Ammit A.J. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am. J. Respir. Cell Mol. Biol. 2008, 39:208-217.
25. Zaman G.J.R., van der Lee M.M.C., Kok J.J., Nelissen R.L.H., Loomans E.E.M.G. Enzyme fragment complementation binding assay for p38α mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors. Assay Drug Dev. Technol. 2006, 4:411-420.